Skip to main content
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TVRD ISIN · US1407553072 LEI · 549300COVOY41P0GZ881 IL Manufacturing
Open in API
Filings indexed 781 across all filing types
Latest filing 2025-06-09 Investor Presentation
Country US United States of America
Listing IL TVRD

About Tvardi Therapeutics, Inc.

https://tvarditherapeutics.com

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered, small molecule therapies. The company's core approach is targeting STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi's therapeutic pipeline is designed to address conditions with significant unmet medical needs, including various forms of cancer and fibrosis-driven diseases. Its clinical trials are evaluating potential treatments for indications such as liver cancer and idiopathic pulmonary fibrosis (IPF).

Recent filings

Filing Released Lang Actions
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 6, 2025, by Tvardi Therapeutics, Inc. The key content is an update about the company's corporate presentation being posted on its website and included as an exhibit. The document does not contain financial statements or detailed financial data but rather announces the availability of a corporate presentation. The length is 3791 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, announcements about report availability or presentations are classified as Investor Presentation (IP) if the document itself is the presentation, or Report Publication Announcement (RPA) if it is just an announcement. Here, the corporate presentation is included as an exhibit, indicating the document itself contains the presentation. Therefore, the classification is Investor Presentation (IP).
2025-06-09 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-06-02 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated May 30, 2025, for Tvardi Therapeutics, Inc. It includes detailed information about a merger, stock issuance, registration rights, and a prospectus for resale of shares. The document is a registration statement for securities offering, which is a capital markets filing related to fundraising and securities issuance. It is not an annual report, earnings release, or any other financial report type. The document is lengthy (15,000 characters) and contains substantive information about the offering and related corporate actions. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-05-30 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The text includes a press release about the completion of enrollment in a clinical trial, which is furnished as an exhibit. The document explicitly states it is a Current Report on Form 8-K and does not contain detailed financial statements or comprehensive financial data. It is not an earnings release or an annual/interim report. The document is relatively short (4196 characters) and primarily serves as a regulatory announcement of a material event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-05-27 English
FORM 8-K
Audit Report / Information Classification · 95% confidence The document is a Form 8-K filed with the SEC by Tvardi Therapeutics, Inc. dated May 12, 2025. It reports the dismissal of the independent registered public accounting firm Ernst & Young LLP and the engagement of Deloitte & Touche LLP as the new auditor. It also references the issuance of a press release announcing financial results for the quarter ended March 31, 2025, but does not itself contain financial statements or detailed financial data. The document primarily concerns changes in the company's auditor and related disclosures, which is typical of an Audit Report / Information filing rather than a full Annual Report or Quarterly Report. The presence of auditor dismissal and engagement details aligns with the Audit Report / Information category (AR). The document length (7856 characters) and content confirm it is not merely an announcement but a substantive report on audit firm changes and related disclosures.
2025-05-13 English
FORM 8-K/A
Interim / Quarterly Report Classification · 95% confidence The document is a Form 8-K/A (Amendment No. 1) filed with the SEC, which amends a previously filed Form 8-K. It updates the Management's Discussion and Analysis (MD&A) and includes unaudited interim financial statements for the quarter ended March 31, 2025. The document references the completion of a merger and provides supplemental financial information for the acquired business. The presence of MD&A and interim financial statements for a quarter indicates this is related to an Interim / Quarterly Report. Although it is filed as an 8-K amendment, the content is substantive financial data and analysis for a quarter, not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-05-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.